Pfizer (PFE) Stock Price, News & Analysis

Company Overview

Pfizer Inc. (NYSE:PFE) is a global biopharmaceutical company that discovers, develops, manufactures and commercializes prescription medicines and vaccines. Its research and commercial activities focus on areas including oncology, inflammation and immunology, internal medicine, hospital care and vaccines.

The company’s portfolio includes widely used products such as the Prevnar family of pneumococcal vaccines, Ibrance for certain breast cancers, Eliquis for preventing blood clots, Xeljanz for inflammatory conditions, and Vyndaqel for transthyretin amyloidosis. Pfizer also developed Comirnaty, an mRNA COVID-19 vaccine, in partnership with BioNTech, and Paxlovid, an oral antiviral treatment for COVID-19.

Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, New York. The company has expanded through internal research, licensing agreements and acquisitions, and serves patients and healthcare providers in markets around the world. Its operations include research and development, manufacturing and commercial activities across North America, Europe, emerging markets and other international regions.

Albert Bourla has served as Pfizer’s chief executive officer since 2019 and as chairman since 2020. The company continues to invest in its pipeline of medicines and vaccines, with research programs spanning oncology, rare diseases, infectious diseases and other areas of significant unmet medical need.

Key Stats

• Today's Range: $27.44 to $28.16
• 50-Day Range: $24.68 to $29.02
• 52-Week Range: $23.62 to $29.21
• Volume: 34.99 million shs
• Average Volume: 30.65 million shs
• Market Capitalization: $158.50 billion
• P/E Ratio: 36.59
• Dividend Yield: 6.19%
• Price Target: $28.39
• Consensus Rating: Hold

Pfizer Stock Analysis - MarketRank™

Pfizer scored higher than 58% of companies evaluated by MarketBeat, and ranked 371st out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Hold

Consensus Rating

Pfizer has received a consensus rating of Hold. The company's average rating score is 2.19, and is based on 1 strong buy rating, 4 buy ratings, 14 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Pfizer is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Pfizer has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -1.01%

Earnings Growth

Earnings for Pfizer are expected to decrease by -1.01% in the coming year, from $2.98 to $2.95 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Pfizer is 36.59, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of Pfizer is 36.59, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 275.68.

Price to Earnings Growth Ratio

Pfizer has a PEG Ratio of 1.89. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Pfizer has a P/B Ratio of 1.82. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.74% of the float of Pfizer has been sold short.

Short Interest Ratio / Days to Cover

Pfizer has a short interest ratio ("days to cover") of 4.9.

Change versus previous month

Short interest in Pfizer has recently increased by 2.42%, indicating that investor sentiment is decreasing.

Dividend

• Score: 4.2 / 5
• Dividend Strength: Strong

Dividend Leadership

Pfizer is a leading dividend payer. It pays a dividend yield of 6.12%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Pfizer has been increasing its dividend for 16 years.

Dividend Coverage

The dividend payout ratio of Pfizer is 226.32%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Pfizer will have a dividend payout ratio of 58.31% next year. This indicates that Pfizer will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.40

News Sentiment

Pfizer has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 50 news articles for Pfizer this week, compared to 9 articles on an average week.

Search Interest

Only 86 people have searched for PFE on MarketBeat in the last 30 days. This is a decrease of -49% compared to the previous 30 days.

MarketBeat Follows

57 people have added Pfizer to their MarketBeat watchlist in the last 30 days. This is an increase of 73% compared to the previous 30 days.

Company Ownership

• Score: 0.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pfizer insiders have not sold or bought any company stock.

Percentage Held by Insiders

0.62% of the stock of Pfizer is held by insiders.

Percentage Held by Institutions

68.36% of the stock of Pfizer is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 9/1 Dividend: 7/24/2026
• Ex-Dividend for 9/1 Dividend: 7/24/2026
• Last Earnings: 8/04/2026
• Dividend Payable: 9/01/2026
• Today: 10/03/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NYSE:PFE
• CIK: 78003
• Web: www.pfizer.com
• Phone: (212) 733-2323
• Fax: 302-655-5049
• Employees: 75,000
• Year Founded: 1849

Price Target and Rating

• Average Price Target for Pfizer: $28.39
• High Price Target: $35.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.19
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.76
• Trailing P/E Ratio: 36.59
• Forward P/E Ratio: 9.33
• P/E Growth: 1.89
• Net Income: $7.77 billion
• Net Margins: 6.80%
• Pretax Margin: 6.61%
• Return on Equity: 19.63%
• Return on Assets: 8.46%

Debt

• Debt-to-Equity Ratio: 0.71
• Current Ratio: 1.27
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $63.70 billion
• Price / Sales: 2.49
• Cash Flow: $4.35 per share
• Price / Cash Flow: 6.40
• Book Value: $15.26 per share
• Price / Book: 1.82

Miscellaneous

• Outstanding Shares: 5,699,674,000
• Free Float: 5,664,336,000
• Market Cap: $158.50 billion
• Optionable: Optionable
• Beta: 0.32